Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Bacteria Test Developer Reiterates Revenue Should Double in 2019

The product expected to drive that outcome is discussed in an H.C. Wainwright & Co. report. In a May 31 research note, analyst Ram Selvaraju reported that H.C. Wainwright & Co. lowered its target price on T2 BioSystems Inc. (TTOO:NASDAQ) to $10 per sha...
Streetwise Reports | June 10, 2019 |

Renewable Energy Firm to Divest Noncore Assets in Beneficial Deal

The advantages of the transaction to this Canadian company are discussed in a CIBC report. In a March 25 research note, CIBC analyst Mark Jarvi reported that Innergex Renewable Energy Inc. (INE:TSX) agreed to sell its Iceland assets, held through a 53.9% interest in H...
Streetwise Reports | April 1, 2019 |

Emerging opportunity in a growing, high-value dermatological market

The following is a transcription of the above video, and The Market Online has edited it for clarity . Kane Biotech Inc. (TSXV:KNE) , a Canadian-based biotech company engaged in the development and commercialization of products that prevent and remove microbial biof...
Ryan Dhillon | April 11, 2024 |

A steady diet of plastic

People eating fish are advised to watch carefully for bones, but how about tiny pieces of plastic? For years it has been known that plastic breaks down into microscopic particles that are consumed by shellfish, fish and mammals higher up the food chain, presentin...
Richard (Rick) Mills | August 21, 2019 |

Theralase is raising up to $5.3M to complete bladder cancer study

Theralase Technologies is announcing a brokered financing raise for up to C$5.3 million Proceeds of the financing will be used to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study Ruvidar is designed to destroy solid core tum...
Coreena Robertson | November 6, 2023 |

Buzz on the Bullboards: From innovating traffic enforcement to cancer breakthroughs

The past week on the TSX has been one for the books, with significant gains driven largely by advancements in the technology sector. The S&P 500 and NASDAQ have hit fresh highs, a clear sign of a hungry market bolstered by technology stocks. This momentum has put a spot...
Jonathon Brown | June 20, 2024 |

BVT's Chairman On Agritech Firm's Massive Growth and Success

Investors are getting excited over a radical new farming technology that is making waves in the media, and in the market. Omri Wallach of Stockhouse Media was recently joined by Michael Collinson, Chairman of the company behind the technology, Bee Vectoring...
Omri Wallach | November 5, 2019 |

Pandemic fears: real and imagined

“Pandemic”. Few words in the English language conjure as much fear. The mere utterance evokes images of dying patients, surgical masks, haz-mat suits, a parade of coffins, helpless doctors and nurses, as the contagion spreads, first striking down the el...
Richard (Rick) Mills | February 25, 2020 |

Living in a virus-controlled world

As the coronavirus pandemic continues to infect populations, though in some countries it is slowing, talk has shifted to re-opening economies, and to manufacturing a vaccine that drug companies hope will not only work, but can be distributed at large enough doses to provide ...
Richard (Rick) Mills | April 24, 2020 |

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/...
Streetwise Reports | November 5, 2019 |
1 2 3 4 5 6 7 8 9 10